A Phase I study showed PTI-188, Pain Therapeutics' metastatic melanoma drug candidate, led to almost 70% of patients having stable disease at the end of the study. A second Phase I trial showed the drug helped about 40% of patients achieve stable disease at the 14th week. The drug is a radiolabeled monoclonal antibody that attaches to and eliminates melanoma tumors.

Full Story:

Related Summaries